Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

<< First  < Prev   1   2   3   Next >  Last >> 
  • 4 Jan 2018 4:48 PM | Hawk Tran (Administrator)

    Funding Available for FUS + Cancer Immunotherapy Projects 


    In June, the Foundation partnered with the Cancer Research Institute to advance the development of new focused ultrasound (FUS) and cancer immunotherapy treatments. Both organizations recognize the intersection of the latest developments in FUS therapy and cancer immunotherapy offers a highly promising opportunity for combination approaches to treat a variety of cancers.

    As a key component of this partnership, we established a grant program to jointly fund research projects that will help investigate new focused ultrasound and cancer immunotherapy combination treatments.

    This first request for proposals seeks preclinical projects to answer the following research question:

    How do different “modes” of focused ultrasound (i.e. ablative vs. non-ablative, thermal vs. mechanical) compare in terms of the immune response generated, and how does this immune response correlate with biological, acoustic and imaging metrics?

    We encourage you to apply and share this opportunity with your colleagues. 

    Projects are eligible for up to $200,000 over two years, and letters of intent are due January 15. 


  • 20 Dec 2017 11:11 AM | Hawk Tran (Administrator)

    New for the 2018 ASCO Annual Meeting, there will be a Merit Award for a VA fellow/oncology trainee.  The Conquer Cancer Foundation Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to the ASCO Annual Meeting and recognized for its scientific merit. 

     

    For the purposes of this award, a VA fellow or oncology trainee is someone:

    (1) who has performed work at a Veterans Affairs facility or,

    (2) whose research describes Veterans Affairs patients, or

    (3) who uses data from Veterans Affairs in his or her research.

    Your abstract must demonstrate one of the above qualifying criteria AND be selected as high-quality for scientific merit. 

     

    The deadline for abstract submissions for the ASCO Annual Meeting is February 13, 2018.  https://asco.confex.com/asco/2018/cfp.cgi


  • 28 Nov 2017 1:43 PM | Hawk Tran (Administrator)

    If you are conducting NIH-funded research that involves human subjects, or are considering applying to NIH for support of such research, we want to call your attention to important changes that may affect how you:

    • select the right NIH funding opportunity announcement
    • write the research strategy and human subjects sections of your application
    • comply with appropriate policies and regulations

    First, familiarize yourself with the new PHS Human Subject and Clinical Trial Information form. For application due dates of January 25, 2018, and beyond, you will be required to use an updated application forms package (FORMS-E), which includes the new human subject and clinical trial form. This form requests human subject and clinical trials information at the study level using discrete form fields, which is a change from current practice. Contract proposals will also require this information. Learn about the new form here.

    Second, take a moment to answer these four questions about your current or proposed research:

    1) Does the study involve human participants?

    2) Are the participants prospectively assigned to an intervention?

    3) Is the study designed to evaluate the effect of the intervention on the participants?

    4) Is the effect that will be evaluated a health-related biomedical or behavioral outcome?

    If the answer to all four questions is yes, then your proposed research meets the NIH definition of a clinical trial. Clarified and broadened in 2014, the definition encompasses a wide range of trial types: mechanistic, exploratory/developmental, pilot/feasibility, behavioral, and more. NIH expanded the clinical trial definition in response to widespread calls from diverse stakeholders for improved reporting of research milestones and outcomes, and for assuring maximal transparency.

    Need help determining whether your study would be considered by NIH to be a clinical trial? See our webpage on the definition that includes case studies, FAQs and other resources that can help. Still unsure?  Contact your NIH program official or the scientific point of contact listed on the funding opportunity announcement to which you are applying.

    Third, familiarize yourself with NIH policy changes related to enhancing stewardship of clinical trials.

    NIH made a number of policy changes to improve the stewardship of clinical trials across the life cycle of the trial. We encourage you to familiarize yourself with all that is changing, including:

    • the requirement to apply to an FOA that specifically allows for the submission of clinical trial applications for due dates beginning January 25, 2018.
    • Good Clinical Practice training expectations for NIH staff, grantees, and contractors that went into effect January 2017.
    • updated peer review criteria that will be included in FOAs for clinical trial applications and solicitations for due dates on/after January 25, 2018.
    • new Human Subject Information form requirements for clinical trials that will be included in updated application forms (FORMS-E) for due dates on/after January 25, 2018, and contract solicitations published as of January 25, 2018.
    • use of a single IRB for non-exempt, multi-site clinical trials for application due dates on/after January 25, 2018.
    • expanded ClinicalTrials.gov registration and reporting to include all NIH supported clinical trials.

    Improving the design, efficiency, and transparency of clinical trials is important because it:

    • respects our ethical obligation to participants to maximize the use of the knowledge from the trials in which they participate
    • facilitates design of clinical trials while reducing unnecessary duplication
    • promotes broad, timely, and responsible dissemination of research information and results
    • fosters responsible stewardship of the public’s investment in biomedical research

    We have developed a new Clinical Trial Requirements for NIH Grantees and Contractors web page to bring together all the information you need to know.  Please review this information carefully.  Your attention to detail will be critical to ensuring successful funding of your clinical trial awards.

    We will be putting out a series of reminder policy notices, training opportunities, and other resources in the NIH Guide to Grants and Contracts, in the NIH Extramural Nexus, and on my blog

    The success of clinical trials relies on the public trust in scientific rigor and ethical oversight.  We all play a critical role in this process.  We are most grateful to you for your help and support.


  • 27 Nov 2017 9:29 AM | Hawk Tran (Administrator)

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/funding/dmrdp

    AIMM Research Award

    • Independent investigators at all academic levels (or equivalent)
    • Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine.
    • Supports novel research concepts and development of enabling technologies.
    • Supports applied research efforts that initiate or enhance potential game-changers; clinical trials are not allowed.
    • Impact and Innovation are important aspects of the AIMM initiative.
    • Projects proposed should be relevant to at least one DoD medical research program area.  However, broadly applicable research projects with the potential to benefit multiple DoD medical research program areas are encouraged. 
    • Applications using synthetic or systems biology-based approaches are highly encouraged.
    • Pre-application (Letter of Intent) is required.
    • Maximum funding of $350,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 18 months.

    A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website at https://www.grants.gov/.  The application package containing the required forms for each award mechanism are found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507

    help@eBrap.org


  • 16 Nov 2017 11:47 AM | Hawk Tran (Administrator)

    VA’s Office of Research and Development (ORD) has partnered with the National Cancer Institute (NCI) to increase the opportunities for Veterans to participate in NCI funded clinical trials.  This effort, known as the NCI And VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE), seeks to fund infrastructure at selected VA Medical Centers to help with overcoming recruitment barriers and facilitating participation in NCI National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) studies.

    The Request for Applications (RFA) can be read here . Interested sites should note the following:

    • Only one application per VA medical center is permitted.
    • There is a Letter of Intent deadline of November 29, 2017 to indicate interest in submitting an application. 
    • Full applications are due on January 10, 2018. 
    • VA Medical Centers interested in submitting an application must work with in collaboration with their VA non-profit corporations/research and education foundations.

    Questions can be directed to CSP@va.gov


  • 15 Nov 2017 1:15 PM | Hawk Tran (Administrator)

    Bring your questions about transitioning to Grants.gov Workspace. The Town Hall is dedicated to listening to your questions and providing answers about the retirement of the Legacy PDF Application Package on December 31, 2017.

    Prerequisite: Watch the webinar video - Getting Started with Grants.gov Workspace: Become a Workspace Wizard

    Workspace is the new standard application method on Grants.gov, so we want to make sure you have the information you need to apply using Workspace on your next grant application.

    CLICK HERE TO REGISTER!


  • 15 Nov 2017 11:33 AM | Hawk Tran (Administrator)

    The FY17 AIMM Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on Grants.gov in November 2017.  Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government, and funding of research projects received in response to the Program Announcement is contingent on the availability of Federal funds.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/pubs/press/2017/17dmrdp-aimmpreann

    AIMM Research Award

    • Independent investigators at all academic levels (or equivalent)
    • Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine.
    • Supports novel research concepts and development of enabling technologies.
    • Supports applied research efforts that initiate or enhance potential game-changers; clinical trials are not allowed.
    • Impact and Innovation are important aspects of the AIMM initiative.
    • Projects proposed should be relevant to at least one DoD medical research program area.  However, broadly applicable research projects with the potential to benefit multiple DoD medical research program areas are encouraged. 
    • Applications using synthetic or systems biology-based approaches are highly encouraged.
    • Pre-application (Letter of Intent) is required.
    • Maximum funding of $350,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 18 months.

    A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website at https://www.grants.gov/.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

     

    Book mark the CDMRP website:

    http://cdmrp.army.mil

     

    Follow CDMRP on Twitter at:

    https://twitter.com/CDMRP

     

    View CDMRP research results on YouTube:

    http://www.youtube.com/user/CDMRP


  • 13 Nov 2017 2:30 PM | Hawk Tran (Administrator)

    Defense Health Program
    Department of Defense Psychological Health and Traumatic Brain Injury Research Program

    Joint Program Committee 5/Military Operational Medicine Research Program

    Funding Opportunities for Fiscal Year 2017

    The FY17 Defense Appropriations Act provides $125 million (M) to the Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation aligned with specific DHA J9 Directorate research program areas, including Joint Program Committee-5/Military Operational Medicine Research Program (JPC-5/MOMRP). This Program Announcement/Funding Opportunity and subsequent awards will be managed and executed by the Congressionally Directed Medical Research Programs (CDMRP) with strategic oversight from JPC-5/MOMRP.  The PH/TBIRP and the JPC-5/MOMRP in collaboration with the Defense Suicide Prevention Office and Service Resiliency Proponents will be seeking applications/proposals to examine the efficacy and effectiveness of peer-to-peer support tools to translate and integrate content into the everyday routines of Service members (SM) to enhance psychological health readiness and mitigate negative behavioral health issues including suicide behaviors.  The expectation of this research is to demonstrate the utility of these peer-to-peer support psychological health readiness tools to benefit our SMs and the public at large.

    FY17 PHTBIRP Program Announcement and General Application Instructions for the following award mechanism is posted on the Grants.gov website. 

    http://cdmrp.army.mil/funding/phtbi

    Peer Support Program (PSP) Translational Research Award – Letter of Intent due January 5, 2018

    Applications to the FY17 PSP Translational Research award should examine the efficacy and effectiveness  of peer-to-peer support interventions to translate and integrate content into the everyday routines of Service members to enhance psychological health readiness and mitigate negative behavioral health issues including suicide behaviors. Applications should focus on research to evaluate the efficacy and effectiveness of peer support programs that could be implemented in the military.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.For more information about the PHTBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 27 Oct 2017 11:46 AM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY17 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

    http://cdmrp.army.mil/funding/kcrp

    Consortium Development Award - Letter of Intent due December 20, 2017

    • An eligible Principal Investigator (who will be the Consortium Director) will be a faculty member at or above Assistant Professor (or equivalent) level. 
    • co-PIs should be at or above Assistant Professor (or equivalent) level.
    • Goal of the Consortium Development Award is to ensure the establishment of the consortium infrastructure for future multi-institutional clinical trials
    • Provides support to create a Coordinating Center and to establish the necessary collaborations at potential Clinical Trial Sites for the development of a multi-institutional kidney clinical effort
    • Minimum of three separate institutes: one Coordinating Center and at least two Clinical Sites (other than the Coordinating Center)
    • Awardee will be eligible to apply for FY19 Consortium Award, if funds are available
    • Maximum funding of $1.0 million total costs
    • Maximum period of performance is 2 years
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    Idea Development Award – Letter of Intent due December 20, 2017

    Established Investigators: 

    • Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
    • Early Career Investigators:
    • Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.
    • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
    • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
    • Preliminary data is required
    • Innovation and Impact are the most important review criteria.
    • Clinical Trials are not allowed
    • Areas of Emphasis include:
    • Microenvironment, Metabolism, Chromatin and Gene Regulation, Rare Cancers, Screening, Early Detection, Novel Imaging Technologies, Liquid Biopsy, Biomarker Development, Prognosis, Targeted Therapies, Immunotherapies, Resistance, Novel Interventions, Surgical, Ablation, Radiation, Prognosis, Managing Toxicity, Survivorship and Patient Experience, Surveillance, Genetic Risk Factors.
    • Maximum funding of $400,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 3 years

    Concept Award – Letter of Intent due December 20, 2017

    • All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.
    • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
    • Emphasis on innovation
    • Clinical trials not allowed
    • Preliminary data not allowed
    • Blinded review
    • Maximum funding of $75,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 1 year

    Translational Research Partnership – Letter of Intent due December 20, 2017

    • The Initiating PI must be at or above the level of Assistant Professor or equivalent.
    • The Partnering PI must be at or above the level of Assistant Professor or equivalent.  Postdoctoral fellows are not eligible to be Partnering PIs
    • ·        Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications
    • ·        Supports translational correlative studies
    • ·        Preliminary data required
    • Clinical trials are not allowed
    • Maximum funding of $600,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    A pre-application (letter of intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application (letter of intent) deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 20 Oct 2017 10:51 AM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY17 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Applications submitted to the FY17 LRP must address at least one of the three Focus Areas listed below:

    •           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

    •           Understand how the underlying genetic components of lupus disease relate to clinical disease characteristics using functional genomic studies.

    •           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genetics of lupus disease in particular tissues, and metabolomics.

    http://cdmrp.army.mil/funding/lrp

    Concept Award – Letter of Intent Due December 21, 2017, Full Application Due January 4, 2018

    • Investigators at all academic levels
    • Supports high-risk studies that have the potential to reveal new avenues for investigation into lupus.
    • Must describe how the new idea will enhance existing knowledge of lupus.
    • Must address at least one of the FY17 LRP Focus Areas
    • Submission of letter of intent is required prior to full application submission
    • Inclusion of preliminary data is encouraged
    • Clinical trials are not allowed
    • Maximum funding of $150,000 for total costs
    • Maximum period of performance is year

    Impact Award – Letter of Intent Due December 21, 2017, Full Application Due January 4, 2018

    • Assistant Professor level or above (or equivalent)
    • Supports new high-risk, high-reward ideas that could lead to critical discoveries or major advancements in the field of lupus research.
    • Must describe how the new idea will enhance existing knowledge of lupus or develop a novel course of investigation.
    • Emphasis is on impact
    • Must address at least one of the FY17 LRP Focus Areas
    • Submission of letter of intent is required prior to full application submission
    • Inclusion of preliminary data is encouraged
    • Clinical trials are not allowed
    • Maximum funding of $525,000 for total costs
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


<< First  < Prev   1   2   3   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software